Rational vaccine development - A new trend in tuberculosis control

New England Journal of Medicine

Volumn 353, Issue 15, 2005, Pages 1624-1625

  Kaplan, Gilla ^a  

^a PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE;

CELLULAR IMMUNITY; DENDRITIC CELL; IMMUNE RESPONSE; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PH MEASUREMENT; PRIORITY JOURNAL; SHORT SURVEY; T LYMPHOCYTE; TUBERCULOSIS; VACCINATION;

ANIMALS; BCG VACCINE; DISEASE MODELS, ANIMAL; GENETIC ENGINEERING; HUMANS; MACROPHAGES; MICE; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, PULMONARY; UREASE; VACCINES, SYNTHETIC;

EID: 26444531050     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcibr053426     Document Type: Short Survey

References (3)

1. Grode L, Seiler P, Baumann S, et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J Clin Invest 2005;115:2472-9.
2. Lazarevic V, Flynn J. CD8+ T cells in tuberculosis. Am J Respir Crit Care Med 2002;166:1116-21.
3. Manca C, Tsenova L, Bergtold A, et al. Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-alpha/beta. Proc Natl Acad Sci U S A 2001;98:5752-7.